search
Back to results

Extended-Release Melatonin in Patients With Rapid Eye Movement Sleep Behavior Disorder

Primary Purpose

Rapid Eye Movement Sleep Behavior Disorder, Parkinson Disease

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Immediate Release Melatonin
Extended Release Melatonin
Sponsored by
Mayo Clinic
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Rapid Eye Movement Sleep Behavior Disorder

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Diagnosed with Parkinson's disease and rapid eye movement sleep behavior disorder.
  • Patient registered to Parkinson's disease database of Mayo Clinic Florida.

Exclusion Criteria:

  • Patients who are using other sleep aids or medications (Clonazepam).
  • Patients who are not willing to undertake 1 week of washout period.
  • Patients who do not sign a consent for research.

Sites / Locations

  • Mayo Clinic FloridaRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Immediate Release Melatonin, Then Extended Release Melatonin

Extended Release Melatonin, Then Immediate Release Melatonin

Arm Description

Subjects will receive immediate release melatonin 5 mg orally at 9 pm every night for 4 weeks. After a washout period of 2 weeks, they then receive extended release melatonin 5 mg orally at 9 pm every night for 4 weeks.

Subjects will receive extended release melatonin 5 mg orally at 9 pm every night for 4 weeks. After a washout period of 2 weeks, they then receive immediate release melatonin 5 mg orally at 9 pm every night for 4 weeks.

Outcomes

Primary Outcome Measures

Change in sleep cycle
Assessed by the self-reported modified Mayo Sleep questionnaire (MSQ) which consists of 8 questions related to sleep behavior in the past month.

Secondary Outcome Measures

Full Information

First Posted
March 23, 2022
Last Updated
May 25, 2023
Sponsor
Mayo Clinic
search

1. Study Identification

Unique Protocol Identification Number
NCT05307770
Brief Title
Extended-Release Melatonin in Patients With Rapid Eye Movement Sleep Behavior Disorder
Official Title
Randomized, Double-Blind, Cross-Over Study Comparing the Efficacy of Immediate and Extended-Release Melatonin as a Supplement Affecting the Sleep Cycle in Patients With Parkinson Disease and Rapid Eye Movement Sleep Behavior Disorder
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Recruiting
Study Start Date
May 1, 2022 (Actual)
Primary Completion Date
April 2024 (Anticipated)
Study Completion Date
April 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Mayo Clinic

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this research is to compare the efficacy of immediate versus extended-release melatonin as a supplement affecting the sleep cycle in patients with Parkinson disease and Rapid Eye Movement Sleep Behavior Disorder.
Detailed Description
Enrolled patients with Parkinson disease and previously diagnosed rapid eye movement sleep behavior disorder, who are being treated at Mayo Clinic in Florida, will be randomized to receive either immediate-release melatonin or extended-release melatonin and then will be crossed over to receive the opposite intervention. The study will consist of two treatment periods of 4 weeks separated by a washout period of 2 weeks.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Rapid Eye Movement Sleep Behavior Disorder, Parkinson Disease

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
50 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Immediate Release Melatonin, Then Extended Release Melatonin
Arm Type
Experimental
Arm Description
Subjects will receive immediate release melatonin 5 mg orally at 9 pm every night for 4 weeks. After a washout period of 2 weeks, they then receive extended release melatonin 5 mg orally at 9 pm every night for 4 weeks.
Arm Title
Extended Release Melatonin, Then Immediate Release Melatonin
Arm Type
Experimental
Arm Description
Subjects will receive extended release melatonin 5 mg orally at 9 pm every night for 4 weeks. After a washout period of 2 weeks, they then receive immediate release melatonin 5 mg orally at 9 pm every night for 4 weeks.
Intervention Type
Dietary Supplement
Intervention Name(s)
Immediate Release Melatonin
Intervention Description
5 mg orally every night at 9 pm for 4 weeks
Intervention Type
Dietary Supplement
Intervention Name(s)
Extended Release Melatonin
Intervention Description
5 mg orally every night at 9 pm for 4 weeks
Primary Outcome Measure Information:
Title
Change in sleep cycle
Description
Assessed by the self-reported modified Mayo Sleep questionnaire (MSQ) which consists of 8 questions related to sleep behavior in the past month.
Time Frame
Baseline and 4 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Diagnosed with Parkinson's disease and rapid eye movement sleep behavior disorder. Patient registered to Parkinson's disease database of Mayo Clinic Florida. Exclusion Criteria: Patients who are using other sleep aids or medications (Clonazepam). Patients who are not willing to undertake 1 week of washout period. Patients who do not sign a consent for research.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Michael Mendiola
Phone
904-953-5064
Email
mendiola.michael@mayo.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Torsak Vimoktayon
Phone
904-953-3238
Email
vimoktayon.torsak@mayo.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Emir Festic, MD, MS
Organizational Affiliation
Mayo Clinic
Official's Role
Principal Investigator
Facility Information:
Facility Name
Mayo Clinic Florida
City
Jacksonville
State/Province
Florida
ZIP/Postal Code
32224
Country
United States
Individual Site Status
Recruiting

12. IPD Sharing Statement

Links:
URL
https://www.mayo.edu/research/clinical-trials
Description
Mayo Clinic Clinical Trials

Learn more about this trial

Extended-Release Melatonin in Patients With Rapid Eye Movement Sleep Behavior Disorder

We'll reach out to this number within 24 hrs